Relapsed or Refractory DLBCL Patients With Either CD19 or CD20 Positive

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Relapsed or Refractory DLBCL Patients With Either CD19 or CD20 Positive trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (1 shown)

UnknownPhase 1

NCT04215016

Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-…

This is a single-arm, open-label, dose escalation, phase I study, aiming to evaluate the safety and efficacy of Autologous Humanized Anti-CD19 and Anti-CD20 Dua…

China18 participantsStarted 2019-12

Treatment: Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells